CYP epoxygenase derived EETs: From cardiovascular protection to human cancer therapy

Current Topics in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1454-1469

  Chen, Chen ^a   Wang, Dao Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Arachidonic acid; Cancer; Cardiovascular disease; CYP epoxygenase; EET; Signal pathways; Therapy

Indexed keywords

1 CYCLOHEXYL 3 DODECYLUREA; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 HYDROXYDECANOIC ACID; 5, 6 EPOXY 8, 11, 14 ICOSATRIENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; ATRIAL NATRIURETIC FACTOR; CYTOCHROME P450; CYTOCHROME P450 2C; CYTOCHROME P450 2C8; CYTOCHROME P450 2J2; CYTOCHROME P450 4A11; DOXORUBICIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GELATINASE B; GLIBENCLAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N ADAMANTYL N DODECYLUREA; NONSTEROID ANTIINFLAMMATORY AGENT; PAXILLINE; TERFENADINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1; WORTMANNIN;

ALLERGY; ANGIOGENESIS; APOPTOSIS; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD VESSEL TONE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; PAIN; PULMONARY VASCULAR DISEASE; THROMBOCYTE AGGREGATION; VASODILATATION;

8,11,14-EICOSATRIENOIC ACID; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TERFENADINE;

EID: 84881353807     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313120007     Document Type: Article

References (168)

1. Wang, D.; Dubois, R. N. Eicosanoids and cancer. Nat Rev Cancer, 2010, 10 (3), 181-93.
2. Wang, D.; Dubois, R. N. Epoxyeicosatrienoic acids: a doubleedged sword in cardiovascular diseases and cancer. J Clin Invest, 2012, 122 (1), 19-22.
3. Cathcart, M. C.; Lysaght, J.; Pidgeon, G. P. Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev, 2011, 30 (3-4), 363-85.
4. Panigrahy, D.; Greene, E. R.; Pozzi, A.; Wang, D. W.; Zeldin, D. C. EET signaling in cancer. Cancer Metastasis Rev, 2011, 30 (3-4), 525-40.
5. Brash, A. R. Arachidonic acid as a bioactive molecule. J Clin Invest, 2001, 107 (11), 1339-45.
6. Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res, 2000, 41 (2), 163-81.
7. Campbell, W. B.; Falck, J. R. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension, 2007, 49 (3), 590-6.
8. Guengerich, F. P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J, 2006, 8 (1), E101-11.
9. Zeldin, D. C. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem, 2001, 276 (39), 36059-62.
10. Imig, J. D. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev, 2012, 92 (1), 101-30.
11. Danielson, P. B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab, 2002, 3 (6), 561-97.
12. Temesvari, M.; Kobori, L.; Paulik, J.; Sarvary, E.; Belic, A.; Monostory, K. Estimation of drug-metabolizing capacity by CYPgenotyping and CYP-expression. J Pharmacol Exp Ther, 2012.
13. Emoto, C.; Murayama, N.; Rostami-Hodjegan, A.; Yamazaki, H. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab, 2010, 11 (8), 678-85.
14. Wang, J. F.; Chou, K. C. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab, 2010, 11 (4), 342-6.
15. Zhao, G.; Wang, J.; Xu, X.; Jing, Y.; Tu, L.; Chen, C.; Cianflone, K.; Wang, P.; Dackor, R. T.; Zeldin, D. C.; Wang, D. W. Epoxyeicosatrienoic acids protect rat hearts against tumor necrosis factoralpha-induced injury. J Lipid Res, 2012.
16. Seubert, J.; Yang, B.; Bradbury, J. A.; Graves, J.; Degraff, L. M.; Gabel, S.; Gooch, R.; Foley, J.; Newman, J.; Mao, L.; Rockman, H. A.; Hammock, B. D.; Murphy, E.; Zeldin, D. C. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res, 2004, 95 (5), 506-14.
17. Xu, D.; Li, N.; He, Y.; Timofeyev, V.; Lu, L.; Tsai, H. J.; Kim, I. H.; Tuteja, D.; Mateo, R. K.; Singapuri, A.; Davis, B. B.; Low, R.; Hammock, B. D.; Chiamvimonvat, N. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A, 2006, 103 (49), 18733-8.
18. Monti, J.; Fischer, J.; Paskas, S.; Heinig, M.; Schulz, H.; Gosele, C.; Heuser, A.; Fischer, R.; Schmidt, C.; Schirdewan, A.; Gross, V.; Hummel, O.; Maatz, H.; Patone, G.; Saar, K.; Vingron, M.; Weldon, S. M.; Lindpaintner, K.; Hammock, B. D.; Rohde, K.; Dietz, R.; Cook, S. A.; Schunck, W. H.; Luft, F. C.; Hubner, N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet, 2008, 40 (5), 529-37.
19. Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D. R.; Fleming, I.; Busse, R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401 (6752), 493-7.
20. Fleming, I.; Rueben, A.; Popp, R.; Fisslthaler, B.; Schrodt, S.; Sander, A.; Haendeler, J.; Falck, J. R.; Morisseau, C.; Hammock, B. D.; Busse, R. Epoxyeicosatrienoic acids regulate Trp channel dependent Ca2+ signaling and hyperpolarization in endothelial cells. Arterioscler Thromb Vasc Biol, 2007, 27 (12), 2612-8.
21. Wang, H.; Lin, L.; Jiang, J.; Wang, Y.; Lu, Z. Y.; Bradbury, J. A.; Lih, F. B.; Wang, D. W.; Zeldin, D. C. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther, 2003, 307 (2), 753-64.
22. Xiao, B.; Li, X.; Yan, J.; Yu, X.; Yang, G.; Xiao, X.; Voltz, J. W.; Zeldin, D. C.; Wang, D. W. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther, 2010, 334 (3), 784-94.
23. Xu, X.; Zhao, C. X.; Wang, L.; Tu, L.; Fang, X.; Zheng, C.; Edin, M. L.; Zeldin, D. C.; Wang, D. W. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes, 2010, 59 (4), 997-1005.
24. Makita, K.; Takahashi, K.; Karara, A.; Jacobson, H. R.; Falck, J. R.; Capdevila, J. H. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest, 1994, 94 (6), 2414-20.
25. Imig, J. D.; Zhao, X.; Capdevila, J. H.; Morisseau, C.; Hammock, B. D. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension, 2002, 39 (2 Pt 2), 690-4.
26. Imig, J. D.; Zhao, X.; Zaharis, C. Z.; Olearczyk, J. J.; Pollock, D. M.; Newman, J. W.; Kim, I. H.; Watanabe, T.; Hammock, B. D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension, 2005, 46 (4), 975-81.
27. Revermann, M.; Barbosa-Sicard, E.; Dony, E.; Schermuly, R. T.; Morisseau, C.; Geisslinger, G.; Fleming, I.; Hammock, B. D.; Brandes, R. P. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens, 2009, 27 (2), 322-31.
28. Zheng, C.; Wang, L.; Li, R.; Ma, B.; Tu, L.; Xu, X.; Dackor, R. T.; Zeldin, D. C.; Wang, D. W. Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats. Am J Respir Cell Mol Biol, 2010, 43 (6), 740-9.
29. Wang, Y. X.; Ulu, A.; Zhang, L. N.; Hammock, B. Soluble epoxide hydrolase in atherosclerosis. Curr Atheroscler Rep, 2010, 12 (3), 174-83.
30. Xu, X.; Zhang, X. A.; Wang, D. W. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev, 2011, 63 (8), 597-609.
31. Herse, F.; Lamarca, B.; Hubel, C. A.; Kaartokallio, T.; Lokki, A. I.; Ekholm, E.; Laivuori, H.; Gauster, M.; Huppertz, B.; Sugulle, M.; Ryan, M. J.; Novotny, S.; Brewer, J.; Park, J. K.; Kacik, M.; Hoyer, J.; Verlohren, S.; Wallukat, G.; Rothe, M.; Luft, F. C.; Muller, D. N.; Schunck, W. H.; Staff, A. C.; Dechend, R. Cytochrome P450 Subfamily 2J Polypeptide 2 Expression and Circulating Epoxyeicosatrienoic Metabolites in Preeclampsia. Circulation, 2012, 126 (25), 2990-9.
32. Wang, Y.; Wei, X.; Xiao, X.; Hui, R.; Card, J. W.; Carey, M. A.; Wang, D. W.; Zeldin, D. C. Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. J Pharmacol Exp Ther, 2005, 314 (2), 522-32.
33. Pozzi, A.; Macias-Perez, I.; Abair, T.; Wei, S.; Su, Y.; Zent, R.; Falck, J. R.; Capdevila, J. H. Characterization of 5,6-and 8,9-epoxyeicosatrienoic acids (5,6-and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem, 2005, 280 (29), 27138-46.
34. Panigrahy, D.; Kaipainen, A.; Greene, E. R.; Huang, S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev, 2010, 29 (4), 723-35.
35. Jiang, J. G.; Chen, C. L.; Card, J. W.; Yang, S.; Chen, J. X.; Fu, X. N.; Ning, Y. G.; Xiao, X.; Zeldin, D. C.; Wang, D. W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res, 2005, 65 (11), 4707-15.
36. Jiang, J. G.; Ning, Y. G.; Chen, C.; Ma, D.; Liu, Z. J.; Yang, S.; Zhou, J.; Xiao, X.; Zhang, X. A.; Edin, M. L.; Card, J. W.; Wang, J.; Zeldin, D. C.; Wang, D. W. Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res, 2007, 67 (14), 6665-74.
37. Pozzi, A.; Ibanez, M. R.; Gatica, A. E.; Yang, S.; Wei, S.; Mei, S.; Falck, J. R.; Capdevila, J. H. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem, 2007, 282 (24), 17685-95.
38. Chen, C.; Li, G.; Liao, W.; Wu, J.; Liu, L.; Ma, D.; Zhou, J.; Elbekai, R. H.; Edin, M. L.; Zeldin, D. C.; Wang, D. W. Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. J Pharmacol Exp Ther, 2009, 329 (3), 908-18.
39. Pozzi, A.; Popescu, V.; Yang, S.; Mei, S.; Shi, M.; Puolitaival, S. M.; Caprioli, R. M.; Capdevila, J. H. The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated. J Biol Chem, 2010, 285 (17), 12840-50.
40. Chen, C.; Wei, X.; Rao, X.; Wu, J.; Yang, S.; Chen, F.; Ma, D.; Zhou, J.; Dackor, R. T.; Zeldin, D. C.; Wang, D. W. Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. J Pharmacol Exp Ther, 2011, 336 (2), 344-55.
41. Sato, M.; Yokoyama, U.; Fujita, T.; Okumura, S.; Ishikawa, Y. The roles of cytochrome p450 in ischemic heart disease. Curr Drug Metab, 2011, 12 (6), 526-32.
42. Estabrook, R. W. A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab Dispos, 2003, 31 (12), 1461-73.
43. Ryan, K. J.; Engel, L. L. Hydroxylation of steroids at carbon 21. J Biol Chem, 1957, 225 (1), 103-14.
44. Estabrook, R. W.; Cooper, D. Y.; Rosenthal, O. The Light Reversible Carbon Monoxide Inhibition of the Steroid C21-Hydroxylase System of the Adrenal Cortex. Biochem Z, 1963, 338, 741-55.
45. Cooper, D. Y.; Levin, S.; Narasimhulu, S.; Rosenthal, O. Photochemical Action Spectrum of the Terminal Oxidase of Mixed Function Oxidase Systems. Science, 1965, 147 (3656), 400-2.
46. Klingenberg, M. Pigments of rat liver microsomes. Arch Biochem Biophys, 1958, 75 (2), 376-86.
47. Cooper, D. Y.; Estabrook, R. W.; Rosenthal, O. The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. J Biol Chem, 1963, 238, 1320-3.
48. Fitzgerald, G. A. Coxibs and cardiovascular disease. N Engl J Med, 2004, 351 (17), 1709-11.
49. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest, 2006, 116 (1), 4-15.
50. Ribeiro, J. D.; Toro, A. A.; Baracat, E. C. Antileukotrienes in the treatment of asthma and allergic rhinitis. J Pediatr (Rio J), 2006, 82 (5 Suppl), S213-21.
51. Chacos, N.; Capdevila, J.; Falck, J. R.; Manna, S.; Martin-Wixtrom, C.; Gill, S. S.; Hammock, B. D.; Estabrook, R. W. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys, 1983, 223 (2), 639-48.
52. Capdevila, J.; Chacos, N.; Werringloer, J.; Prough, R. A.; Estabrook, R. W. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci U S A, 1981, 78 (9), 5362-6.
53. Capdevila, J.; Parkhill, L.; Chacos, N.; Okita, R.; Masters, B. S.; Estabrook, R. W. The oxidative metabolism of arachidonic acid by purified cytochromes P-450. Biochem Biophys Res Commun, 1981, 101 (4), 1357-63.
54. Morrison, A. R.; Pascoe, N. Metabolism of arachidonate through NADPH-dependent oxygenase of renal cortex. Proc Natl Acad Sci U S A, 1981, 78 (12), 7375-8.
55. Oliw, E. H.; Oates, J. A. Oxygenation of arachidonic acid by hepatic microsomes of the rabbit. Mechanism of biosynthesis of two vicinal dihydroxyeicosatrienoic acids. Biochim Biophys Acta, 1981, 666 (3), 327-40.
56. Capdevila, J.; Marnett, L. J.; Chacos, N.; Prough, R. A.; Estabrook, R. W. Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyicosatetraenoic acids. Proc Natl Acad Sci U S A, 1982, 79 (3), 767-70.
57. Oliw, E. H. Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases. Prog Lipid Res, 1994, 33 (3), 329-54.
58. Ishizuka, T.; Cheng, J.; Singh, H.; Vitto, M. D.; Manthati, V. L.; Falck, J. R.; Laniado-Schwartzman, M. 20-Hydroxyeicosatet raenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther, 2008, 324 (1), 103-10.
59. Miyata, N.; Seki, T.; Tanaka, Y.; Omura, T.; Taniguchi, K.; Doi, M.; Bandou, K.; Kametani, S.; Sato, M.; Okuyama, S.; Cambj-Sapunar, L.; Harder, D. R.; Roman, R. J. Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke. J Pharmacol Exp Ther, 2005, 314 (1), 77-85.
60. Renic, M.; Klaus, J. A.; Omura, T.; Kawashima, N.; Onishi, M.; Miyata, N.; Koehler, R. C.; Harder, D. R.; Roman, R. J. Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab, 2009, 29 (3), 629-39.
61. Zeldin, D. C.; Foley, J.; Ma, J.; Boyle, J. E.; Pascual, J. M.; Moomaw, C. R.; Tomer, K. B.; Steenbergen, C.; Wu, S. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol, 1996, 50 (5), 1111-7.
62. Guengerich, F. P.; Rendic, S. Update information on drug metabolism systems--2009, part I. Curr Drug Metab, 2010, 11 (1), 1-3.
63. Kaspera, R.; Totah, R. A. Epoxyeicosatrienoic acids: formation, metabolism and potential role in tissue physiology and pathophysiology. Expert Opin Drug Metab Toxicol, 2009, 5 (7), 757-71.
64. Ayajiki, K.; Fujioka, H.; Toda, N.; Okada, S.; Minamiyama, Y.; Imaoka, S.; Funae, Y.; Watanabe, S.; Nakamura, A.; Okamura, T. Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation. Hypertens Res, 2003, 26 (3), 237-43.
65. Stark, K.; Dostalek, M.; Guengerich, F. P. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J, 2008, 275 (14), 3706-17.
66. Fromel, T.; Kohlstedt, K.; Popp, R.; Yin, X.; Awwad, K.; Barbosa-Sicard, E.; Thomas, A. C.; Lieberz, R.; Mayr, M.; Fleming, I. Cytochrome P4502S1: a novel monocyte/macrophage fatty acid epoxygenase in human atherosclerotic plaques. Basic Res Cardiol, 2013, 108 (1), 319.
67. Zeldin, D. C.; Foley, J.; Goldsworthy, S. M.; Cook, M. E.; Boyle, J. E.; Ma, J.; Moomaw, C. R.; Tomer, K. B.; Steenbergen, C.; Wu, S. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol, 1997, 51 (6), 931-43.
68. Klose, T. S.; Blaisdell, J. A.; Goldstein, J. A. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol, 1999, 13 (6), 289-95.
69. Campbell, W. B.; Gebremedhin, D.; Pratt, P. F.; Harder, D. R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res, 1996, 78 (3), 415-23.
70. Zeldin, D. C.; Kobayashi, J.; Falck, J. R.; Winder, B. S.; Hammock, B. D.; Snapper, J. R.; Capdevila, J. H. Regio-and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem, 1993, 268 (9), 6402-7.
71. Yu, Z.; Xu, F.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res, 2000, 87 (11), 992-8.
72. Imig, J. D.; Hammock, B. D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov, 2009, 8 (10), 794-805.
73. Larsen, B. T.; Gutterman, D. D.; Hatoum, O. A. Emerging role of epoxyeicosatrienoic acids in coronary vascular function. Eur J Clin Invest, 2006, 36 (5), 293-300.
74. Moffat, M. P.; Ward, C. A.; Bend, J. R.; Mock, T.; Farhangkhoee, P.; Karmazyn, M. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol, 1993, 264 (4 Pt 2), H1154-60.
75. Xiao, Y. F.; Huang, L.; Morgan, J. P. Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol, 1998, 508(Pt 3), 777-92.
76. Lee, H. C.; Lu, T.; Weintraub, N. L.; VanRollins, M.; Spector, A. A.; Shibata, E. F. Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol, 1999, 519, 153-68.
77. Xiao, Y. F.; Ke, Q.; Seubert, J. M.; Bradbury, J. A.; Graves, J.; Degraff, L. M.; Falck, J. R.; Krausz, K.; Gelboin, H. V.; Morgan, J. P.; Zeldin, D. C. Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2. Mol Pharmacol, 2004, 66 (6), 1607-16.
78. Lu, T.; Ye, D.; Wang, X.; Seubert, J. M.; Graves, J. P.; Bradbury, J. A.; Zeldin, D. C.; Lee, H. C. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms. J Physiol, 2006, 575 (Pt 2), 627-44.
79. Nithipatikom, K.; Moore, J. M.; Isbell, M. A.; Falck, J. R.; Gross, G. J. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol, 2006, 291 (2), H537-42.
80. Zhang, Y.; El-Sikhry, H.; Chaudhary, K. R.; Batchu, S. N.; Shayeganpour, A.; Jukar, T. O.; Bradbury, J. A.; Graves, J. P.; DeGraff, L. M.; Myers, P.; Rouse, D. C.; Foley, J.; Nyska, A.; Zeldin, D. C.; Seubert, J. M. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol, 2009, 297 (1), H37-46.
81. Katragadda, D.; Batchu, S. N.; Cho, W. J.; Chaudhary, K. R.; Falck, J. R.; Seubert, J. M. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J Mol Cell Cardiol, 2009, 46 (6), 867-75.
82. Guglielmino, K.; Jackson, K.; Harris, T. R.; Vu, V.; Dong, H.; Dutrow, G.; Evans, J. E.; Graham, J.; Cummings, B. P.; Havel, P. J.; Chiamvimonvat, N.; Despa, S.; Hammock, B. D.; Despa, F. Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. Am J Physiol Heart Circ Physiol, 2012, 303 (7), H853-62.
83. Wang, H. X.; Zhang, D. M.; Zeng, X. J.; Mu, J.; Yang, H.; Lu, L. Q.; Zhang, L. K. Upregulation of cytochrome P450 2J3/11,12-epoxyeicosatrienoic acid inhibits apoptosis in neonatal rat cardiomyocytes by a caspase-dependent pathway. Cytokine, 2012, 60 (2), 360-8.
84. Seubert, J. M.; Sinal, C. J.; Graves, J.; DeGraff, L. M.; Bradbury, J. A.; Lee, C. R.; Goralski, K.; Carey, M. A.; Luria, A.; Newman, J. W.; Hammock, B. D.; Falck, J. R.; Roberts, H.; Rockman, H. A.; Murphy, E.; Zeldin, D. C. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res, 2006, 99 (4), 442-50.
85. Dhanasekaran, A.; Gruenloh, S. K.; Buonaccorsi, J. N.; Zhang, R.; Gross, G. J.; Falck, J. R.; Patel, P. K.; Jacobs, E. R.; Medhora, M. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol, 2008, 294 (2), H724-35.
86. Ai, D.; Pang, W.; Li, N.; Xu, M.; Jones, P. D.; Yang, J.; Zhang, Y.; Chiamvimonvat, N.; Shyy, J. Y.; Hammock, B. D.; Zhu, Y. Soluble epoxide hydrolase plays an essential role in angiotensin IIinduced cardiac hypertrophy. Proc Natl Acad Sci U S A, 2009, 106 (2), 564-9.
87. Imig, J. D.; Navar, L. G.; Roman, R. J.; Reddy, K. K.; Falck, J. R. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol, 1996, 7 (11), 2364-70.
88. Gauthier, K. M.; Deeter, C.; Krishna, U. M.; Reddy, Y. K.; Bondlela, M.; Falck, J. R.; Campbell, W. B. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res, 2002, 90 (9), 1028-36.
89. Gauthier, K. M.; Jagadeesh, S. G.; Falck, J. R.; Campbell, W. B. 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15-and 5,6-EET antagonist in bovine coronary arteries. Hypertension, 2003, 42 (4), 555-61.
90. Baron, A.; Frieden, M.; Beny, J. L. Epoxyeicosatrienoic acids activate a high-conductance, Ca(2+)-dependent K + channel on pig coronary artery endothelial cells. J Physiol, 1997, 504(Pt 3), 537-43.
91. Larsen, B. T.; Miura, H.; Hatoum, O. A.; Campbell, W. B.; Hammock, B. D.; Zeldin, D. C.; Falck, J. R.; Gutterman, D. D. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am J Physiol Heart Circ Physiol, 2006, 290 (2), H491-9.
92. Imig, J. D.; Inscho, E. W.; Deichmann, P. C.; Reddy, K. M.; Falck, J. R. Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension, 1999, 33 (1 Pt 2), 408-13.
93. Vriens, J.; Owsianik, G.; Fisslthaler, B.; Suzuki, M.; Janssens, A.; Voets, T.; Morisseau, C.; Hammock, B. D.; Fleming, I.; Busse, R.; Nilius, B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res, 2005, 97 (9), 908-15.
94. Wang, R. X.; Chai, Q.; Lu, T.; Lee, H. C. Activation of vascular BK channels by docosahexaenoic acid is dependent on cytochrome P450 epoxygenase activity. Cardiovasc Res, 2011, 90 (2), 344-52.
95. Jiang, J. G.; Chen, R. J.; Xiao, B.; Yang, S.; Wang, J. N.; Wang, Y.; Cowart, L. A.; Xiao, X.; Wang, D. W.; Xia, Y. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat, 2007, 82 (1-4), 162-74.
96. Hercule, H. C.; Schunck, W. H.; Gross, V.; Seringer, J.; Leung, F. P.; Weldon, S. M.; da Costa Goncalves, A.; Huang, Y.; Luft, F. C.; Gollasch, M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol, 2009, 29 (1), 54-60.
97. Coffman, T. M. Under pressure: the search for the essential mechanisms of hypertension. Nat Med, 2011, 17 (11), 1402-9.
98. Capdevila, J. H.; Falck, J. R.; Imig, J. D. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int, 2007, 72 (6), 683-9.
99. Huang, H.; Morisseau, C.; Wang, J.; Yang, T.; Falck, J. R.; Hammock, B. D.; Wang, M. H. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol, 2007, 293 (1), F342-9.
100. Athirakul, K.; Bradbury, J. A.; Graves, J. P.; DeGraff, L. M.; Ma, J.; Zhao, Y.; Couse, J. F.; Quigley, R.; Harder, D. R.; Zhao, X.; Imig, J. D.; Pedersen, T. L.; Newman, J. W.; Hammock, B. D.; Conley, A. J.; Korach, K. S.; Coffman, T. M.; Zeldin, D. C. Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J, 2008, 22 (12), 4096-108.
101. Liclican, E. L.; Doumad, A. B.; Wang, J.; Li, J.; Falck, J. R.; Stier, C. T. Jr.; Carroll, M. A. Inhibition of the adenosine2A receptorepoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. Hypertension, 2009, 54 (6), 1284-90.
102. Lee, C. R.; Imig, J. D.; Edin, M. L.; Foley, J.; DeGraff, L. M.; Bradbury, J. A.; Graves, J. P.; Lih, F. B.; Clark, J.; Myers, P.; Perrow, A. L.; Lepp, A. N.; Kannon, M. A.; Ronnekleiv, O. K.; Alkayed, N. J.; Falck, J. R.; Tomer, K. B.; Zeldin, D. C. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J, 2010, 24 (10), 3770-81.
103. Pidkovka, N.; Rao, R.; Mei, S.; Gong, Y.; Harris, R. C.; Wang, W. H.; Capdevila, J. H. Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by ERK1/2-mediated phosphorylation. J Biol Chem, 2013.
104. Ma, J.; Zhang, L.; Han, W.; Shen, T.; Ma, C.; Liu, Y.; Nie, X.; Liu, M.; Ran, Y.; Zhu, D. Activation of JNK/c-Jun is required for the proliferation, survival, and angiogenesis induced by EET in pulmonary artery endothelial cells. J Lipid Res, 2012, 53 (6), 1093-105.
105. Chiamvimonvat, N.; Ho, C. M.; Tsai, H. J.; Hammock, B. D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol, 2007, 50 (3), 225-37.
106. Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci U S A, 1999, 96 (16), 8849-54.
107. Zhao, X.; Yamamoto, T.; Newman, J. W.; Kim, I. H.; Watanabe, T.; Hammock, B. D.; Stewart, J.; Pollock, J. S.; Pollock, D. M.; Imig, J. D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol, 2004, 15 (5), 1244-53.
108. Loch, D.; Hoey, A.; Morisseau, C.; Hammock, B. O.; Brown, L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys, 2007, 47 (1), 87-98.
109. Pecic, S.; Deng, S. X.; Morisseau, C.; Hammock, B. D.; Landry, D. W. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett, 2012, 22 (1), 601-5.
110. Sudhahar, V.; Shaw, S.; Imig, J. D. Epoxyeicosatrienoic acid analogs and vascular function. Curr Med Chem, 2010, 17 (12), 1181-90.
111. Fitzpatrick, F. A.; Ennis, M. D.; Baze, M. E.; Wynalda, M. A.; McGee, J. E.; Liggett, W. F. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem, 1986, 261 (32), 15334-8.
112. Heizer, M. L.; McKinney, J. S.; Ellis, E. F. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke, 1991, 22 (11), 1389-93.
113. Jiang, H.; McGiff, J. C.; Quilley, J.; Sacerdoti, D.; Reddy, L. M.; Falck, J. R.; Zhang, F.; Lerea, K. M.; Wong, P. Y. Identification of 5,6-trans-epoxyeicosatrienoic acid in the phospholipids of red blood cells. J Biol Chem, 2004, 279 (35), 36412-8.
114. Krotz, F.; Riexinger, T.; Buerkle, M. A.; Nithipatikom, K.; Gloe, T.; Sohn, H. Y.; Campbell, W. B.; Pohl, U. Membrane-potentialdependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol, 2004, 24 (3), 595-600.
115. Silvestre, J. S.; Mallat, Z.; Tedgui, A.; Levy, B. I. Post-ischaemic neovascularization and inflammation. Cardiovasc Res, 2008, 78 (2), 242-9.
116. Ross, R. Atherosclerosis--an inflammatory disease. N Engl J Med, 1999, 340 (2), 115-26.
117. Lee, C. R.; North, K. E.; Bray, M. S.; Couper, D. J.; Heiss, G.; Zeldin, D. C. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet Genomics, 2007, 17 (5), 349-58.
118. Ercan, B.; Ayaz, L.; Cicek, D.; Tamer, L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct, 2008, 26 (3), 309-13.
119. Hermann, M.; Hellermann, J. P.; Quitzau, K.; Hoffmann, M. M.; Gasser, T.; Meinertz, T.; Munzel, T.; Fleming, I.; Luscher, T. F. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease--the ENCORE Trials. Atherosclerosis, 2009, 207 (2), 476-9.
120. Ulu, A.; Davis, B. B.; Tsai, H. J.; Kim, I. H.; Morisseau, C.; Inceoglu, B.; Fiehn, O.; Hammock, B. D.; Weiss, R. H. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol, 2008, 52 (4), 314-23.
121. Zhang, L. N.; Vincelette, J.; Cheng, Y.; Mehra, U.; Chen, D.; Anandan, S. K.; Gless, R.; Webb, H. K.; Wang, Y. X. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol, 2009, 29 (9), 1265-70.
122. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420 (6917), 868-74.
123. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell, 2011, 144 (5), 646-74.
124. Collins, T.; Read, M. A.; Neish, A. S.; Whitley, M. Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J, 1995, 9 (10), 899-909.
125. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 1999, 285 (5431), 1276-9.
126. Fleming, I.; Michaelis, U. R.; Bredenkotter, D.; Fisslthaler, B.; Dehghani, F.; Brandes, R. P.; Busse, R. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res, 2001, 88 (1), 44-51.
127. Moshal, K. S.; Zeldin, D. C.; Sithu, S. D.; Sen, U.; Tyagi, N.; Kumar, M.; Hughes, W. M. Jr.; Metreveli, N.; Rosenberger, D. S.; Singh, M.; Vacek, T. P.; Rodriguez, W. E.; Ayotunde, A.; Tyagi, S. C. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia. J Cell Physiol, 2008, 215 (3), 771-81.
128. Morin, C.; Sirois, M.; Echave, V.; Gomes, M. M.; Rousseau, E. EET displays anti-inflammatory effects in TNF-alpha stimulated human bronchi: putative role of CPI-17. Am J Respir Cell Mol Biol, 2008, 38 (2), 192-201.
129. Deng, Y.; Edin, M. L.; Theken, K. N.; Schuck, R. N.; Flake, G. P.; Kannon, M. A.; DeGraff, L. M.; Lih, F. B.; Foley, J.; Bradbury, J. A.; Graves, J. P.; Tomer, K. B.; Falck, J. R.; Zeldin, D. C.; Lee, C. R. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J, 2011, 25 (2), 703-13.
130. Chen, G.; Wang, P.; Zhao, G.; Xu, G.; Gruzdev, A.; Zeldin, D. C.; Wang, D. W. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice. Prostaglandins Other Lipid Mediat, 2011, 96 (1-4), 63-71.
131. Bystrom, J.; Wray, J. A.; Sugden, M. C.; Holness, M. J.; Swales, K. E.; Warner, T. D.; Edin, M. L.; Zeldin, D. C.; Gilroy, D. W.; Bishop-Bailey, D. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One, 2011, 6 (10), e26591.
132. Schmelzer, K. R.; Kubala, L.; Newman, J. W.; Kim, I. H.; Eiserich, J. P.; Hammock, B. D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci U S A, 2005, 102 (28), 9772-7.
133. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T. S.; Fang, X.; Zhu, Y.; Spector, A. A.; Gill, S.; Morisseau, C.; Hammock, B. D.; Shyy, J. Y. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A, 2005, 102 (46), 16747-52.
134. Fleming, I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat, 2007, 82 (1-4), 60-7.
135. Fleming, I.; Fisslthaler, B.; Michaelis, U. R.; Kiss, L.; Popp, R.; Busse, R. The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells. Pflugers Arch, 2001, 442 (4), 511-8.
136. Potente, M.; Michaelis, U. R.; Fisslthaler, B.; Busse, R.; Fleming, I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and upregulation of cyclin D1. J Biol Chem, 2002, 277 (18), 15671-6.
137. Potente, M.; Fisslthaler, B.; Busse, R.; Fleming, I. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J Biol Chem, 2003, 278 (32), 29619-25.
138. Chen, J. K.; Capdevila, J.; Harris, R. C. Cytochrome p450 epoxygenase metabolism of arachidonic acid inhibits apoptosis. Mol Cell Biol, 2001, 21 (18), 6322-31.
139. Dhanasekaran, A.; Al-Saghir, R.; Lopez, B.; Zhu, D.; Gutterman, D. D.; Jacobs, E. R.; Medhora, M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol, 2006, 291 (2), H517-31.
140. Yang, S.; Lin, L.; Chen, J. X.; Lee, C. R.; Seubert, J. M.; Wang, Y.; Wang, H.; Chao, Z. R.; Tao, D. D.; Gong, J. P.; Lu, Z. Y.; Wang, D. W.; Zeldin, D. C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factoralpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol, 2007, 293 (1), H142-51.
141. Li, R.; Xu, X.; Chen, C.; Yu, X.; Edin, M. L.; Degraff, L. M.; Lee, C. R.; Zeldin, D. C.; Wang, D. W. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. Prostaglandins Other Lipid Mediat, 2012, 99 (3-4), 68-78.
142. Evan, G.; Littlewood, T. A matter of life and cell death. Science, 1998, 281 (5381), 1317-22.
143. Michaelis, U. R.; Fisslthaler, B.; Medhora, M.; Harder, D.; Fleming, I.; Busse, R. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). FASEB J, 2003, 17 (6), 770-2.
144. Jiang, M.; Mezentsev, A.; Kemp, R.; Byun, K.; Falck, J. R.; Miano, J. M.; Nasjletti, A.; Abraham, N. G.; Laniado-Schwartzman, M. Smooth muscle--specific expression of CYP4A1 induces endothelial sprouting in renal arterial microvessels. Circ Res, 2004, 94 (2), 167-74.
145. Michaelis, U. R.; Fisslthaler, B.; Barbosa-Sicard, E.; Falck, J. R.; Fleming, I.; Busse, R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci, 2005, 118 (Pt 23), 5489-98.
146. Zhang, B.; Cao, H.; Rao, G. N. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem, 2006, 281 (2), 905-14.
147. Seta, F.; Patil, K.; Bellner, L.; Mezentsev, A.; Kemp, R.; Dunn, M. W.; Schwartzman, M. L. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat, 2007, 84 (3-4), 116-27.
148. Yan, G.; Chen, S.; You, B.; Sun, J. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res, 2008, 78 (2), 308-14.
149. Webler, A. C.; Popp, R.; Korff, T.; Michaelis, U. R.; Urbich, C.; Busse, R.; Fleming, I. Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler Thromb Vasc Biol, 2008, 28 (6), 1123-9.
150. Xu, D. Y.; Davis, B. B.; Wang, Z. H.; Zhao, S. P.; Wasti, B.; Liu, Z. L.; Li, N.; Morisseau, C.; Chiamvimonvat, N.; Hammock, B. D. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARgamma to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. International journal of cardiology, 2012.
151. Pozzi, A.; Yan, X.; Macias-Perez, I.; Wei, S.; Hata, A. N.; Breyer, R. M.; Morrow, J. D.; Capdevila, J. H. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem, 2004, 279 (28), 29797-804.
152. Rodriguez-Antona, C.; Gomez, A.; Karlgren, M.; Sim, S. C.; Ingelman-Sundberg, M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum Genet, 2010, 127 (1), 1-17.
153. McLemore, T. L.; Adelberg, S.; Czerwinski, M.; Hubbard, W. C.; Yu, S. J.; Storeng, R.; Wood, T. G.; Hines, R. N.; Boyd, M. R. Altered regulation of the cytochrome P4501A1 gene: novel inducerindependent gene expression in pulmonary carcinoma cell lines. J Natl Cancer Inst, 1989, 81 (23), 1787-94.
154. Oude Ophuis, M. B.; van Lieshout, E. M.; Roelofs, H. M.; Peters, W. H.; Manni, J. J. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer, 1998, 82 (5), 936-43.
155. Rahman, A.; Korzekwa, K. R.; Grogan, J.; Gonzalez, F. J.; Harris, J. W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res, 1994, 54 (21), 5543-6.
156. Dai, D.; Zeldin, D. C.; Blaisdell, J. A.; Chanas, B.; Coulter, S. J.; Ghanayem, B. I.; Goldstein, J. A. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics, 2001, 11 (7), 597-607.
157. Jernstrom, H.; Bageman, E.; Rose, C.; Jonsson, P. E.; Ingvar, C. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer, 2009, 101 (11), 1817-23.
158. Isomura, Y.; Yamaji, Y.; Ohta, M.; Seto, M.; Asaoka, Y.; Tanaka, Y.; Sasaki, T.; Nakai, Y.; Sasahira, N.; Isayama, H.; Tada, M.; Yoshida, H.; Kawabe, T.; Omata, M.; Koike, K. A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer. J Gastroenterol, 2010, 45 (10), 1045-52.
159. Knupfer, H.; Stanitz, D.; Preiss, R. CYP2C9 polymorphisms in human tumors. Anticancer Res, 2006, 26 (1A), 299-305.
160. Lafite, P.; Dijols, S.; Buisson, D.; Macherey, A. C.; Zeldin, D. C.; Dansette, P. M.; Mansuy, D. Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2. Bioorg Med Chem Lett, 2006, 16 (10), 2777-80.
161. Lafite, P.; Dijols, S.; Zeldin, D. C.; Dansette, P. M.; Mansuy, D. Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2. Arch Biochem Biophys, 2007, 464 (2), 155-68.
162. Cheng, L. M.; Jiang, J. G.; Sun, Z. Y.; Chen, C.; Dackor, R. T.; Zeldin, D. C.; Wang, D. W. The epoxyeicosatrienoic acidstimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells. Acta Pharmacol Sin, 2010, 31 (2), 211-8.
163. Liu, L.; Chen, C.; Gong, W.; Li, Y.; Edin, M. L.; Zeldin, D. C.; Wang, D. W. Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide. J Pharmacol Exp Ther, 2011, 339 (2), 451-63.
164. Panigrahy, D.; Edin, M. L.; Lee, C. R.; Huang, S.; Bielenberg, D. R.; Butterfield, C. E.; Barnes, C. M.; Mammoto, A.; Mammoto, T.; Luria, A.; Benny, O.; Chaponis, D. M.; Dudley, A. C.; Greene, E. R.; Vergilio, J. A.; Pietramaggiori, G.; Scherer-Pietramaggiori, S. S.; Short, S. M.; Seth, M.; Lih, F. B.; Tomer, K. B.; Yang, J.; Schwendener, R. A.; Hammock, B. D.; Falck, J. R.; Manthati, V. L.; Ingber, D. E.; Kaipainen, A.; D'Amore, P. A.; Kieran, M. W.; Zeldin, D. C. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest, 2012, 122 (1), 178-91.
165. Nithipatikom, K.; Brody, D. M.; Tang, A. T.; Manthati, V. L.; Falck, J. R.; Williams, C. L.; Campbell, W. B. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci, 2010, 101 (12), 2629-36.
166. Zagorac, D.; Jakovcevic, D.; Gebremedhin, D.; Harder, D. R. Antiangiogenic effect of inhibitors of cytochrome P450 on rats with glioblastoma multiforme. J Cereb Blood Flow Metab, 2008, 28 (8), 1431-9.
167. Tsuchiya, Y.; Nakajima, M.; Takagi, S.; Taniya, T.; Yokoi, T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res, 2006, 66 (18), 9090-8.
168. Chen, F.; Chen, C.; Yang, S.; Gong, W.; Wang, Y.; Cianflone, K.; Tang, J.; Wang, D. W. Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2. PLoS One, 2012, 7 (6), e39197.